PRAMO is among the 14 best biotech start-ups at the EIT Health Catapult semifinals of the European Union.
PRAMO is eligible for the INVEST Grant. This allows national and international private investors to be reimbursed up to 15% of their capital invested in our company by BAFA- Federal Office of Economics and Export Control.